These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 26560486)

  • 1. Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced non-small cell lung cancer.
    Daga H; Takeda K; Okada H; Miyazaki M; Ueda S; Kaneda H; Okamoto I; Yoh K; Goto K; Konishi K; Sarashina A; Tanaka T; Kaiser R; Nakagawa K
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1225-33. PubMed ID: 26560486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3).
    Forster M; Hackshaw A; De Pas T; Cobo M; Garrido P; Summers Y; Dingemans AC; Flynn M; Schnell D; von Wangenheim U; Loembé AB; Kaiser R; Lee SM
    Lung Cancer; 2018 Jun; 120():27-33. PubMed ID: 29748012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy.
    Yamamoto N; Kenmotsu H; Goto K; Takeda K; Kato T; Takeda M; Horinouchi H; Saito I; Sarashina A; Tanaka T; Morsli N; Nakagawa K
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):685-694. PubMed ID: 30073583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients.
    Ellis PM; Kaiser R; Zhao Y; Stopfer P; Gyorffy S; Hanna N
    Clin Cancer Res; 2010 May; 16(10):2881-9. PubMed ID: 20460487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial.
    Hanna NH; Kaiser R; Sullivan RN; Aren OR; Ahn MJ; Tiangco B; Voccia I; Pawel JV; Kovcin V; Agulnik J; Gaschler-Markefski B; Barrueco J; Sikken P; Schloss C; Kim JH;
    Lung Cancer; 2016 Dec; 102():65-73. PubMed ID: 27987591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer.
    Chow LQ; Blais N; Jonker DJ; Laurie SA; Diab SG; Canil C; McWilliam M; Thall A; Ruiz-Garcia A; Zhang K; Tye L; Chao RC; Camidge DR
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):709-22. PubMed ID: 21989766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.
    Soria JC; Adjei AA; Bahleda R; Besse B; Ferte C; Planchard D; Zhou J; Ware J; Morrissey K; Shankar G; Lin W; Schutzman JL; Dy GK; Groen HJM
    Eur J Cancer; 2017 Nov; 86():186-196. PubMed ID: 28992562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerability of nintedanib (BIBF 1120) in combination with docetaxel: a phase 1 study in Japanese patients with previously treated non-small-cell lung cancer.
    Okamoto I; Miyazaki M; Takeda M; Terashima M; Azuma K; Hayashi H; Kaneda H; Kurata T; Tsurutani J; Seto T; Hirai F; Konishi K; Sarashina A; Yagi N; Kaiser R; Nakagawa K
    J Thorac Oncol; 2015 Feb; 10(2):346-52. PubMed ID: 25299232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer.
    Ellis PM; Chu QS; Leighl N; Laurie SA; Fritsch H; Gaschler-Markefski B; Gyorffy S; Munzert G
    Clin Lung Cancer; 2013 Jan; 14(1):19-27. PubMed ID: 22658814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting.
    Greystoke A; Steele N; Arkenau HT; Blackhall F; Md Haris N; Lindsay CR; Califano R; Voskoboynik M; Summers Y; So K; Ghiorghiu D; Dymond AW; Hossack S; Plummer R; Dean E
    Br J Cancer; 2017 Sep; 117(7):938-946. PubMed ID: 28950288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study.
    Blais N; Camidge DR; Jonker DJ; Soulières D; Laurie SA; Diab SG; Ruiz-Garcia A; Thall A; Zhang K; Chao RC; Chow LQ
    Invest New Drugs; 2013 Dec; 31(6):1487-98. PubMed ID: 23963796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of weekly docetaxel plus nintedanib: A phase I trial after first-line chemotherapy failure in NSCLC.
    Westeel V; Schuette W; Urban T; Radonjic D; von Wangenheim U; Lorence RM; Reck M
    PLoS One; 2023; 18(10):e0292307. PubMed ID: 37847688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non-small-cell lung cancer.
    Yamamoto N; Satouchi M; Doi T; Fujiwara Y; Yanagitani N; Kawa Y; Yoh K; Leopold L; Munteanu M; Sawada T; Han S; Noguchi K; Nishio M
    Invest New Drugs; 2024 Jun; 42(3):261-271. PubMed ID: 38530565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma.
    Camidge DR; Blais N; Jonker DJ; Soulières D; Doebele RC; Ruiz-Garcia A; Thall A; Zhang K; Laurie SA; Chao RC; Chow LQ
    Cancer Chemother Pharmacol; 2013 Feb; 71(2):307-19. PubMed ID: 23108697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of selumetinib as a monotherapy, or in combination with docetaxel as second-line therapy, in Japanese patients with advanced solid malignancies or non-small cell lung cancer.
    Seto T; Hirai F; Saka H; Kogure Y; Yoh K; Niho S; Fukase K; Shimada H; Sasai M; Fukino K
    Jpn J Clin Oncol; 2018 Jan; 48(1):31-42. PubMed ID: 29136201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer.
    Noor ZS; Goldman JW; Lawler WE; Telivala B; Braiteh F; DiCarlo BA; Kennedy K; Adams B; Wang X; Jones B; Slamon DJ; Garon EB
    Lung Cancer; 2019 Sep; 135():104-109. PubMed ID: 31446981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC.
    Huang M; Gong Y; Zhu J; Qin Y; Peng F; Ren L; Ding Z; Liu Y; Cai C; Wang Y; Lu Y
    Invest New Drugs; 2020 Apr; 38(2):478-484. PubMed ID: 31231786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC).
    Mizugaki H; Yamamoto N; Nokihara H; Fujiwara Y; Horinouchi H; Kanda S; Kitazono S; Yagishita S; Xiong H; Qian J; Hashiba H; Shepherd SP; Giranda V; Tamura T
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1063-72. PubMed ID: 26433581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma.
    Palmer DH; Ma YT; Peck-Radosavljevic M; Ross P; Graham J; Fartoux L; Deptala A; Studeny M; Schnell D; Hocke J; Loembé AB; Meyer T
    Br J Cancer; 2018 May; 118(9):1162-1168. PubMed ID: 29563636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors.
    de Braud F; Cascinu S; Spitaleri G; Pilz K; Clementi L; Liu D; Sikken P; De Pas T
    Ann Oncol; 2015 Nov; 26(11):2341-6. PubMed ID: 26395347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.